News

Subscribe to our mailing list to receive research, advocacy and other updates from MS Australia

Categories
Categories
date range
date range

MS Australia News

20 May 2025

CEO Rohan Greenland shares an enormous thank you to everyone who took part in or supported this year’s iconic May 50K, and outlines MS Australia’s advocacy priorities in the post-election…

20 May 2025

Researchers studying identical twins and laboratory models have found that certain gut bacteria may be linked to MS development….

20 May 2025

New clinical trial results show that tolebrutinib reduces the risk of disability progression in non-relapsing secondary progressive MS and is as effective as teriflunomide in relapsing MS….

19 May 2025

This National Volunteer Week, we are celebrating the contributions of the members of MS Australia’s Lived Experience Expert Panel, who share why they’re so passionate about volunteering….

6 May 2025

The Pharmaceutical Benefits Advisory Committee (PBAC) will consider adding ocrelizumab (Ocrevus®) via subcutaneous delivery to the PBS for relapsing remitting MS….

30 April 2025

As Australians head toward the 2025 Federal Election, The Raw Nerve, MS Australia’s official podcast, gathered leading experts to explore a crucial question: why should health be a top election…

MS Canada and MS Australia lead new global initiative into the prevention and ultra-early detection of MS

23 April 2025

A new international effort to prevent multiple sclerosis (MS) is officially underway, as researchers, clinicians, people living with MS, and MS organisations from around the world gather in Lisbon, Portugal,…

23 April 2025

We are on the cusp of May, the most important month in the global MS calendar….

23 April 2025

Researchers have discovered that genetic changes accumulate more rapidly in MS brain lesions than in non-lesion tissue, with distinct patterns emerging in the lesions….

23 April 2025

A pilot study has found an existing online cognitive behavioural therapy (CBT) program from Germany is highly acceptable to people with multiple sclerosis (MS) in Australia and achieved reduced levels…

23 April 2025

Phase 3 trials did not show a clear advantage of evobrutinib compared to current treatments for people with relapsing MS….

23 April 2025

Luigi wanted his legacy to be one that made a difference. Through his generous bequest to MS Plus, he ensured that people living with multiple sclerosis would receive the support…

Newsletter subscription

  • Enter your details

From our CEO